Eli Lilly and Company Retevmo shows major reduction in cancer recurrence risk trial
Eli Lilly's Retevmo cut cancer recurrence or death risk by 83% in the Phase 3 LIBRETTO-432 trial of 151 NSCLC patients. 24-month EFS hit 92%

seen from Peru
seen from United States

seen from Malaysia

seen from Malaysia

seen from Malaysia
seen from United Kingdom

seen from Malaysia
seen from United States
seen from Canada

seen from Malaysia
seen from United States
seen from Malaysia
seen from United States

seen from United States
seen from Canada
seen from China
seen from China
seen from Canada
seen from Taiwan

seen from Canada
Eli Lilly and Company Retevmo shows major reduction in cancer recurrence risk trial
Eli Lilly's Retevmo cut cancer recurrence or death risk by 83% in the Phase 3 LIBRETTO-432 trial of 151 NSCLC patients. 24-month EFS hit 92%